CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 710 enrolled
Drug / intervention
Atazanavir +3 moredrug
Likely dose
Atazanavir 400 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01003990
NCT01003990Phase 3Completed
CompareCT.gov

Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study

Bristol-Myers Squibb·interventional·Posted Oct 29, 2009·Updated May 11, 2017

In Brief

A Phase 3 clinical trial evaluating Atazanavir, Atazanavir/Ritonavir, and 2 other interventions for HIV. Completed, enrolled 710 participants across 88 sites in 25 countries.

Detailed Summary

The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect long-term safety information on the treated population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesArgentina, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, France, Guatemala, Hungary, Indonesia, Italy, Malaysia, Mexico, Panama, Peru, Portugal, Puerto Rico, Russia, Singapore, South Africa, Spain, Taiwan, Thailand, United States
Collaborators--

Timeline

Phase 3CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedOct 29, 2009
Enrollment StartOct 1, 2002
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 13.3 yearsPosted 16.7 years ago

Interventions

Atazanavirdrug

Tablets, Oral, 400 mg, once daily, indefinitely

Atazanavir/Ritonavirdrug

Tablets, Oral, 300/100 mg, once daily, indefinitely

Tenofovir/Emtricitabinedrug

Tablets, Oral, 300/200 mg, once daily, indefinitely

Lopinavir/ritonavirdrug

Tablets, Oral, 400/100 mg, twice daily, indefinitely